Edesa Biotech EDSA 深 滬
等待開盤 09-24 09:30:00 美东时间
3.97
-0.100
-2.46%
華盛通- 最 高4.09
- 今 開4.02
- 成交量 2.55万股
- 最 低 3.97
- 昨 收 4.07
- 總市值 3827.49万
- 52周最高 20.32
- 市盈率 靜 --
- 換手率 0.26%
- 52周最低 0.72
- 委 比 -40.07%
- 總股本 964.10万
- 歷史最高 133.70
- 量 比 0.56
- 振 幅 2.95%
- 歷史最低 0.72
- 每 手 1
- 風險率 3.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Edesa Biotech Stock Sinks After Fresh Capital Raise
Edesa Biotech, Inc. (NASDAQ:EDSA) shares fell nearly 13% in Thursday premarket trading after the company priced a $25 million public stock offering. Edesa Biotech shares fell 18.27% to $4.70 in Wednesday’s after-market session, putting the stock on traders’ radars. The move followed the company’s Q3...
08-20 18:20
Edesa Biotech prices $25M equity offering
Edesa Biotech (EDSA) priced an underwritten public offering expected to raise about $25M in gross proceeds through the sale of common shares and warrants. The offering includes 3.87M common shares and...
08-20 15:32
Edesa Biotech shares are trading lower after the company announced a proposed public offering.
Edesa Biotech shares are trading lower after the company announced a proposed public offering.
08-20 04:06
Edesa Biotech Commences Common Stock Offering; Terms Undisclosed
Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has commenced an underwritten public offering of its common shares (or pre-funded warran...
08-20 04:01
Edesa Biotech Announces Proposed Public Offering
Edesa Biotech, Inc. has initiated an underwritten public offering of its common shares and accompanying warrants, with an option for underwriters to purchase additional shares. Guggenheim Securities is the sole book-running manager. Proceeds will be used for general corporate purposes, including R&D and manufacturing. The offering is subject to SEC registration and market conditions.
08-19 20:01
Edesa Biotech Q3 EPS $(0.60) Misses $(0.58) Estimate
Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.58) by 3.45 percent. This is a 140 percent decrease over losses of $(0.25) per share from the same period last year.
08-14 04:45
Edesa Biotech Announces Exploratory Data For Its Anti-TLR4 Monoclonal Antibody Paridiprubart In Patients With Acute Kidney Injury And Respiratory Distress; Analyses Demonstrate Mortality Reduction
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today reported favorable exploratory data for paridiprubart, its
06-05 21:25
美股牛股 | 绩优股普涨！NXXT飙升100%，毛利润增长逾两倍；ALAB大涨13%
绩优股普涨！NXXT飙升100%，毛利润增长逾两倍；美物科技大涨97%，募资开发AI护肤平台；ALAB大涨13%，Q1业绩炸裂、指引超预期>>
05-20 18:45
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) shares rose 94.0% to $0.55 during Mon...
05-19 01:05
Edesa Biotech Q2 EPS $(0.49) Misses $(0.26) Estimate
Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.26) by 88.46 percent. This is a 63.33 percent decrease over losses of $(0.30) per share from
05-15 04:50
